1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsOligodendroglioma Research Fund (Community Research Fund Program) is sponsored by National Brain Tumor Society (NBTS). This fund supports promising research specifically targeted at creating new treatments for oligodendroglioma and improving patients' lives.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Oligodendroglioma Research Fund Join NBTS’s campaign to raise awareness about the importance of biomarker testing and clinical trials for patients with brain tumors. Brain Tumor Support Conversations Caregiver Support Conversations Grief Support Conversations Patient & Caregiver Toolkit Patient & Care Partner Resources Connect with our expert team for personalized brain tumor navigation, including the resources and support you need.
Current Research Initiatives NBTS offers a training program for research advocates to serve as a link between patients and scientists, government officials, and industry leaders.
Advocate From Your State® Brain Tumor Awareness Month Glioblastoma Awareness Day Childhood Cancer Awareness Month Brain Tumor Investment Fund® Corporate & Foundation Partnerships Shop to Fuel Breakthroughs Oligodendroglioma Research Fund Through the Community Research Fund Program, the Oligodendroglioma Research Fund supports promising research specifically targeted at creating new treatments for oligodendroglioma and improving patients’ lives.
From 2013 to today, NBTS has funded a total of $2 million in grants to 11 researchers across nine different institutions, all focused on oligodendroglioma and related low-grade glioma research.
During this period, NBTS’s strategy to address the problem has focused on funding research projects that revealed genetic risk factors, established models capable of testing potential treatments, built scientific infrastructure to predict if treatments will work, launched novel therapeutic approaches, and helped propel a groundbreaking treatment toward a pivotal clinical trial lead by a biopharma prepared to bring a new therapy to patients.
The latest Oligodendroglioma Research Progress Report focuses specifically on NBTS funded research related to oligodendroglioma. It describes results over a seven-year time span and exciting next steps to drive research forward aimed at novel treatments and ultimately, cures.
Support the Oligo Research Fund To direct your gift to the Oligodendroglioma Research Fund, go to our donation page and select “direct my gift” under the Gift Designation header. The menu will provide an option to support the Oligodendroglioma Research Fund. Innovative Models Developed for Testing Treatments Dr. Anders Persson, University of California San Francisco New Strategy Identified for Eliminating Brain Tumors Drs.
Mario Suva & David Louis, Massachusetts General Hospital Targeting Mutant IDH 1/2 with Vorasidenib (AG-881) in Low-Grade Gliomas Dr. Ingo Mellinghoff, Memorial Sloan Kettering Cancer Leads Discovered About the Causes of Brain Cancer Drs.
Robert Jenkins & Daniel Lachance, Mayo Clinic Registry Built to Learn from Every Patient and Determine Response to Treatment Dr. Elizabeth Claus, Yale University Identifying Risk Factors for Oligodendroglioma Drs.
Robert Jenkins & Daniel Lachance, Mayo Clinic AI Platform Established to Predict Brain Tumor Behavior Dan Brat and Lee Cooper, Emory and Northwestern University International Consortium of Researchers Establishes Open Dataset Tracking Low-Grade Gliomas including Oligodendroglioma Dr. Roel Verhaak, The Jackson Laboratory Triggering the Body’s Immune System to Fight Back Dr. Samuel Cheshier, Standford
According to the current listing, eligibility includes: Researchers focused on oligodendroglioma and related low-grade glioma research. Confirm the full requirements in the official notice before applying.
The current listing shows see official notice (NBTS has funded $2 million in grants to 11 researchers since 2013). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Oligodendroglioma Research Fund (Community Research Fund Program) is funded by National Brain Tumor Society (NBTS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
ARPA-H's HEARING program (ARPA-H-SOL-26-154) — Hearing Enhancement through ARtificially Intelligent NeurotechnoloGy — held its Proposers' Day on June 8, 2026 and set Solution Summary deadlines for June 29 with Full Proposals due August 14. Single prime awardee, multiple Other Transaction Agreements, three integrated technical areas spanning intracortical recording and stimulation devices, wearable dynamic sound modulators, and AI-based auditory read/write algorithms. The first phase runs 18 months; the full effort runs 4.5 years through first-in-human clinical studies. For neurotech teams that have spent a decade in cochlear-implant or visual-prosthesis space, this is the moment the federal government bet on auditory cortex over the cochlea.
Read articleA Nature poll finds three-quarters of American scientists are considering working abroad. ERC applications from U.S. researchers have tripled. France and the EU pledged €500 million to recruit them. Inside the brain drain reshaping global science — and what it means for grant strategy.
Read article